Home / Market News / $PYXS
benzinga Corporate Catalyst Impact 55/100 ● neutral

Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement

Sep 29, 2026, 8:24 PM UTC · Primary ticker $PYXS

Pyxis Oncology has terminated its previously announced $150 million at-the-market (ATM) stock offering, confirming that no shares were sold under the agreement. This move frees up capacity under their registration statement for future offerings, but signals a pause in their immediate equity fundraising plans.

Pyxis Oncology has formally terminated its $150 million at-the-market (ATM) offering, which was established to sell common stock through Leerink Partners. The key takeaway is that despite having the facility in place, the company did not sell any shares under this specific agreement. This action is largely neutral in the short term as it simply closes a facility that wasn't utilized, but it does free up the registration statement for other potential offerings, indicating flexibility in future financing strategies. For traders, this means the immediate dilution risk from this particular ATM offering is removed, but the company retains the Sales Agreement and could initiate new offerings with a new prospectus supplement, suggesting that future equity raises remain a possibility. The long-term implication is that Pyxis Oncology still has avenues for capital raising, which is common for biotech firms, but this specific ATM is no longer active.

$PYXS neutral Direct subject of the filing
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.